Dr. Randa Tao

Claim this profile

Huntsman Cancer Institute/University of Utah

Studies Esophageal Cancer
Studies Esophageal Adenocarcinoma
4 reported clinical trials
11 drugs studied

Area of expertise

1Esophageal Cancer
Randa Tao has run 3 trials for Esophageal Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage I
2Esophageal Adenocarcinoma
Randa Tao has run 2 trials for Esophageal Adenocarcinoma. Some of their research focus areas include:
Stage IV
HER2 negative
Stage I

Affiliated Hospitals

Image of trial facility.
Huntsman Cancer Institute/University Of Utah
Image of trial facility.
University Of Utah Sugarhouse Health Center

Clinical Trials Randa Tao is currently running

Image of trial facility.

Chemotherapy + Radiotherapy

for Esophageal and Gastric Cancer

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Image of trial facility.

Hypoxia-Guided Radiation

for Esophageal Cancer

This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI. All patients will receive a baseline FMISO positron emission tomography (PET) and MRI to identify levels of hypoxia. Patients with tumor hypoxia will receive a higher dose of radiation therapy. Subjects who do not have hypoxic tumors will be treated with the standard-of-care radiation regimen. After fraction 10 of radiation therapy, an additional MRI will be performed. If this interim MRI demonstrates little or no response (as defined in Section 6), an optional boost radiation dose can be administered. Trial enrollment will be conducted in two parts. In Part 1, eight patients will be enrolled. After all eight patients have completed the 30 day dose-limiting toxicity (DLT) period, enrollment will be placed on hold and safety will be evaluated. During the interim analysis, one additional patient will be allowed to be enrolled in the trial. If the trial meets stopping rules as described in Section 11.3, the trial will be re-evaluated by the Data and Safety Monitoring Committee (DSMC) and the Principal Investigator. However, if the rate of DLTs remains below the unacceptable toxicity rate, enrollment will open to the enrollment of eight more patients.
Recruiting1 award Phase 17 criteria

More about Randa Tao

Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Randa Tao has experience with
  • Radiation Therapy
  • FMISO PET CT
  • Capecitabine
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Randa Tao specialize in?
Is Randa Tao currently recruiting for clinical trials?
Are there any treatments that Randa Tao has studied deeply?
What is the best way to schedule an appointment with Randa Tao?
What is the office address of Randa Tao?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security